WO2026105063 - LONG-ACTING IL-15 AGONIST FOR TREATING BLADDER CANCER
National phase entry is expected:
Publication Number
WO/2026/105063
Publication Date
21.05.2026
International Application No.
PCT/IB2025/061669
International Filing Date
14.11.2025
Title **
[English]
LONG-ACTING IL-15 AGONIST FOR TREATING BLADDER CANCER
[French]
AGONISTE IL-15 À ACTION PROLONGÉE POUR LE TRAITEMENT DU CANCER DE LA VESSIE
Applicants **
SUZHOU FORLONG BIOTECHNOLOGY CO., LTD.
Inventors
JI, En
WEI, Duo
XU, Xiajun
Priority Data
PCT/CN2024/132036
14.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2557 | |
| EPO | Filing, Examination, Granting | 12190 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2385 | |
| USA | Filing, Examination, Granting | 4740 |

Total:
24,179
Contact Us
Abstract[English]
A method of treating bladder cancer with an agonistic IL-15 complex, alone or in combination with BCG, is described.[French]
L'invention concerne une méthode de traitement du cancer de la vessie au moyen d'un complexe IL-15 agoniste, seul ou en combinaison avec le BCG.